Fig. 7. The drug combination of marimastat and varespladib significantly inhibits the size of dermal lesions induced by B. asper and E. ocellatus venoms when delivered up to 1 hour after venom challenge.

Mice (n = 5) were ID injected with B. asper (150 µg) or E. ocellatus (39 µg) venom and then ID injected in the same location at 0 minutes (i.e. a second injection immediately) post-venom challenge with drug vehicle control (98.48% PBS, 1.52% DMSO; Veh) or at 0-, 5-, 15-, or 60-minutes post-venom challenge with marimastat and varespladib (60 and 19 µg, respectively; MV). After 72 hours experimental animals were euthanised and their lesions excised, quantified, and photographed. a Representative images of the lesions resulting from each treatment group (black scale bar represents 3 mm). Bar graphs summarising the ability of MV to inhibit skin lesion formation caused by b B. asper and c E. ocellatus venoms at 0-, 5-, 15-, and 60-minutes post-venom challenge. * Signifies that value is significantly different than that of the drug vehicle control for that venom as determined by a one-way ANOVA followed by Dunnett’s multiple comparisons test (P < 0.05, n = 5 [all drug treatments] or 10 [vehicle controls] biologically independent animals). ANOVA statistics for individual statistically analysed graphs are: b F(4,25) = 14.27, P = 0.0000034, c F(4,25) = 12.88, P = 0.00000795. Data are presented as mean values ± SD and the individual values for each lesion are shown as points within each of the bars. Source data are provided as a Source Data file.